Patient-centered, comparative effectiveness of esophageal cancer screening: Protocol for a comparative effectiveness research study to inform guidelines for evidence-based approach to screening and surveillance endoscopy

BMC Health Services Research

Volumn 12, Issue 1, 2012, Pages

  Kramer, Jennifer R ^a,b   Arney, Jennifer ^a,b,d   Chen, John ^a,b   Richardson, Peter ^a,b   Duan, Zhigang ^a,b   Street, Richard L ^a,c   Hinojosa Lindsey, Marilyn ^a,b   Naik, Aanand D ^a,b   El Serag, Hashem B ^a,b  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS A AND M UNIVERSITY   (United States)

^d UNIVERSITY OF HOUSTON   (United States)

Author keywords

Barretts esophagus; Comparative effectiveness research; Endoscopy; Mixed methods research

Indexed keywords

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; EARLY DIAGNOSIS; ENDOSCOPY; EPIDEMIOLOGY; ESOPHAGUS TUMOR; EVALUATION; EVIDENCE BASED MEDICINE; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH SURVEY; HUMAN; MALE; MEDICARE; METHODOLOGY; MIDDLE AGED; PATIENT CARE; PRACTICE GUIDELINE; QUALITATIVE RESEARCH; STANDARD; UNITED STATES; VETERAN;

ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; COMPARATIVE EFFECTIVENESS RESEARCH; EARLY DETECTION OF CANCER; EFFECT MODIFIER, EPIDEMIOLOGIC; ENDOSCOPY; ESOPHAGEAL NEOPLASMS; EVIDENCE-BASED MEDICINE; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MEDICARE; MIDDLE AGED; PATIENT-CENTERED CARE; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; QUALITATIVE RESEARCH; UNITED STATES; VETERANS;

EID: 84865339228     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-12-288     Document Type: Review

References (41)

1. The changing epidemiology of esophageal cancer. Blot WJ, McLaughlin JK, Semin Oncol 1999 26 2 8 10566604
2. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Devesa SS, Blot WJ, Fraumeni JF Jr, Cancer 1998 83 2049 2053 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2 9827707
3. Barrett's Esophagus, a complication of GERD. Sampliner RE, Current Treatment Options in Gastroenterology 2002 5 45 50 10.1007/s11938-002-0006-1 11792237
4. The epidemic of esophageal adenocarcinoma. El-Serag HB, Gastroenterol Clin North Am 2002 31 421 440 10.1016/S0889-8553(02)00016-X 12134611
5. Temporal trends (1973-1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB, Am J Gastroenterol 2003 98 1627 1633 12873590
6. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. El-Serag HB, Mason AC, Petersen N, Key CR, Gut 2002 50 368 372 10.1136/gut.50.3.368 11839716
7. Epidemiology of columnar-lined esophagus and adenocarcinoma. Cameron AJ, Gastroenterol Clin North Am 1997 26 487 494 10.1016/S0889-8553(05)70308-3 9309399
8. A critical review of the diagnosis and management of Barrett's oesophagus: the AGA Chicago workshop. Sharma P, McQuaid K, Dent J, et al. Gastroenterol 2004 127 310 330 10.1053/j.gastro.2004.04.010
9. The relationship between gastroesophageal reflux disease and its complications with Barrett's Esophagus. Eisen GM, Sandler RS, Murray S, Gottfried M, Am J Gastroenterol 1997 92 27 31 8995932
10. GORGE Consortium. Risk factors for Barrett's Esophagus in community-based practice. Lieberman DA, Oehlke M, Helfand M, Am J Gastroenterol 1997 92 1293 1297 9260792
11. Updated guidelines for the diagnosis, surveillance, and therapy of Barrett's Esophagus. Sampliner RE, Am J Gastroenterol 2002 97 1888 1895 10.1111/j.1572-0241.2002.05910.x 12190150
12. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's Esophagus. The Practice Parameters Committee of the American College of Gastroenterology. Sampliner RE, Am J Gastroenterol 1998 93 1028 1032 10.1111/j.1572-0241.1998.00362.x 9672324
13. Clinical practice. Barrett's Esophagus. Spechler SJ, New England Journal of Medicine 2002 346 836 842 10.1056/NEJMcp012118 11893796
14. Prevention of adenocarcinoma by reversing Barrett's Esophagus with mucosal ablation. Sampliner RE, World J Surg 2003 27 1026 1029 10.1007/s00268-003-7056-y 12917762
15. Spechler S, Managing Barrett's Oesophagus. Br Med J 2003 326 892 894 22931307
16. Management of Barrett's Esophagus: a national study of practice patterns and their cost implications. Gross CP, Canto MI, Hixson J, Powe NR, Am J Gastroenterol 1999 94 3440 3447 10.1111/j.1572-0241.1999.01606.x 10606300
17. Receipt of previous diagnoses and endoscopy and outcome from esophageal adenocarcinoma: a population-based study with temporal trends. Cooper GS, Kou TD, Chak A, Am J Gastroenterol 2009 104 1356 1362 10.1038/ajg.2009.159 19491849
18. Endoscopic surveillance for Barrett's oesophagus: the patients' perspective. Cooper SC, El-agib A, Dar S, Eur J Gastroenterol Hepatol 2009 21 850 854 10.1097/MEG.0b013e328318ed2d 19598328
19. Health-related quality of life in patients with Barrett's esophagus: a systematic review. Crockett SD, Lippmann QK, Dellon ES, Shaheen NJ, Clin Gastroenterol Hepatol 2009 7 613 623 10.1016/j.cgh.2009.02.024 19281858
20. The burden of upper gastrointestinal endoscopy in patients with Barrett's esophagus. Kruijshaar ME, Kerkhof M, Siersema PD, Steyerberg EW, Homs MY, Essink-Bot ML, Endoscopy 2006 38 873 878 10.1055/s-2006-944613 17019759
21. Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low. Kruijshaar ME, Siersema PD, Janssens AC, Kerkhof M, Steyerberg EW, Essink-Bot ML, Gastrointest Endosc 2007 65 26 30 10.1016/j.gie.2006.05.030 17185076
22. The perception of cancer risk in patients with prevalent Barrett's esophagus enrolled in an endoscopic surveillance program. Shaheen NJ, Green B, Medapalli RK, et al. Gastroenterology 2005 129 429 436 16083700
23. A new scale for assessing perceptions of chance: a validation study. Woloshin S, Schwartz LM, Byram S, Fischhoff B, Welch HG, Med Decis Making 2000 20 298 307 10.1177/0272989X0002000306 10929852
24. Effect of a new diagnosis of Barrett's Esophagus on insurance status. Shaheen NJ, Dulai GS, Ascher B, Mitchell KL, Schmitz SM, Am J Gastroenterol 2005 100 577 580 10.1111/j.1572-0241.2005.41422.x 15743354
25. Should patients with Barrett's Oesophagus be kept under surveillance? The case against. Barritt AS, Shaheen NJ, Best Practices Research Clinical Gastroenterology 2008 22 741 750 10.1016/j.bpg.2007.12.005
26. Screening and surveillance for Barrett's Esophagus in high-risk groups: a cost-utility analysis. Inadomi JM, Sampliner RE, Lagergren J, Lieberman D, Fendrick AM, Vakil N, Ann Intern Med 2003 138 176 186 12558356
27. A cost-utility analysis of ablative therapy for Barrett's Esophagus. Inadomi JM, Somsouk M, Madanick RD, Thomas JP, Shaheen NJ, Gastroenterology 2009 136 2101 2114 10.1053/j.gastro.2009.02.062 19272389
28. Medication compliance and persistence: Terminology and definitions. Cramer JA, Roy A, Burrell A, et al. Value in Health 2008 11 44 47 10.1111/j.1524-4733.2007.00213.x 18237359
29. A checklist for medication compliance and persistence studies using retrospective databases. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M, Value in Health 2007 10 3 12 10.1111/j.1524-4733. 2006.00139.x 17261111
30. The assessment of refill compliance using pharmacy records: methods, validity, and applications. Steiner JF, Prochazka AV, J Clin Epidemiol 1997 50 105 116 10.1016/S0895-4356(96)00268-5 9048695
31. Depth interviewing. Miller WL, Crabtree BF, Doing QualitativeResearch Thousand Oaks: Sage, Crabtree BF, Miller WL, 2 1999 89 108
32. Sampling in qualitative inquiry. Kuzel AJ, Doing Qualitative Research Thousand Oaks: Sage, Crabtree BF, Miller WL, 2 1999 33 46
33. The significance of saturation. Morse J, Qual Health Res 1995 5 147 149 10.1177/104973239500500201
34. Qualitative data analysis for applied policy research. Ritchie J, Spencer L, Analyzing Qualitative Data New York: Routledge, Bryman A, Burgess RG, 1994 173 94
35. Glaser BG, Strauss AL, The Discovery of Grounded Theory: Strategies for Qualitative Research Chicago: Aldine 1967
36. Waitzkin H, The Politics of Medical Encounters: How Patients and Doctors Deal with Social Problems New Haven: Yale University Press 1991
37. A theory of medical decision making and health: fuzzy trace theory. Reyna VF, Med Decis Making 2008 28 850 865 10.1177/0272989X08327066 19015287
38. A reasoned action approach to health promotion. Fishbein M, Med Decis Making 2008 28 834 844 10.1177/0272989X08326092 19015289
39. The neglected purpose of comparative-effectiveness research. Naik AD, Petersen LA, N Engl J Med 2009 360 1929 1931 10.1056/NEJMp0902195 19420362
40. Methodological standards and patient-centeredness in comparative effectiveness research. Methodology Committee of the PCORI, J Am Med Assoc 2012 307 1636 1640
41. Is it time for medicine-based evidence? Concato J, J Am Med Assoc 2012 307 1641 1643 10.1001/jama.2012.482